Ontology highlight
ABSTRACT:
SUBMITTER: Garcia-Miralles M
PROVIDER: S-EPMC5752291 | biostudies-literature | 2017 Dec
REPOSITORIES: biostudies-literature
Garcia-Miralles Marta M Geva Michal M Tan Jing Ying JY Yusof Nur Amirah Binte Mohammad NABM Cha Yoonjeong Y Kusko Rebecca R Tan Liang Juin LJ Xu Xiaohong X Grossman Iris I Orbach Aric A Hayden Michael R MR Pouladi Mahmoud A MA
JCI insight 20171207 23
Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the appearance of disease phenotypes or in advanced stages of disease in the YAC128 mouse model of HD. In the early treatment cohort, animals received 0, 10, or 30 mg/kg pridopidine for a period of 10.5 months. In the late treatment cohort, animals were treated for 8 weeks with 0 mg/k ...[more]